Immuneering (IMRX) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pyxis Oncology (PYXS) has outperformed Immuneering (IMRX) over the past year, losing 21.2% versus a loss of 36.8%. Over five years, PYXS leads with a -82.9% price change compared with -84.5% for IMRX. Immuneering is the larger company by market cap ($249.7 million vs $240.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | PYXS |
|---|---|---|
| Share price | $3.86 | $2.01 |
| Market cap | $249.73M | $240.11M |
| 1-day change | +0.78% | -0.50% |
| YTD return | -41.34% | +74.78% |
| 1-year return | -36.82% | -21.18% |
| 5-year return | -84.47% | -82.92% |
| EPS (TTM) | $-0.94 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.48 | $5.55 |
| 52-week low | $3.74 | $1.03 |
| Distance from 52-week high | -54.48% | -63.78% |
| Average volume | 693.70K | 1.26M |
| Shares outstanding | 64.70M | 119.46M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYXS has outperformed IMRX by 15.6 percentage points over the past year.
IMRX vs PYXS FAQ
Which is bigger, Immuneering or Pyxis Oncology?
Immuneering (IMRX) is larger, with a market capitalization of $249.73M compared with $240.11M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, IMRX or PYXS?
PYXS returned -21.18% over the past 12 months, compared with -36.82% for IMRX (price return, excluding dividends). Past performance does not predict future results.
Are Immuneering and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.